Investors

Investor Relations

Landing - Corporate Profile Text

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

More events are coming soon.

News Releases

July 8, 2024
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock